ZLAB
Zai Lab Limited American Depositary Shares
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
25.90
▼ 0.12 (0.46%)
MARKET · —
Price
Open
25.98
Prev close
26.02
Day high
26.29
Day low
25.74
Volume
872.32K
Market cap
$2.92B
P/E (TTM)
—
52W range
15.96 – 35.45
Trailing performance
Returnvs SPY
1W
+0.42%
+1.8%
1M
+32.16%
+28.4%
3M
+36.18%
+33.1%
6M
+29.79%
+18.7%
YTD
+47.45%
+35.2%
1Y
-22.36%
-42.4%
3Y
+7.75%
-66.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.92B
Enterprise value$2.56B
Revenue (TTM)$449.61M
Gross profit$16.98M
EBITDA$-248.17M
Net income$-188.21M
EPS (TTM)$-1.70
Free cash flow$-83.96M
Total cash$617.52M
Total debt$254.58M
Book value / share$5.96
Shares outstanding112.27M
Float97.11M
Short % of float5.94%
Dividend yield—
Beta (5Y)0.78
Valuation & profitability ratios
Trailing P/E—
Forward P/E-12.62
PEG ratio—
Price / sales—
Price / book4.36
EV / revenue5.69
EV / EBITDA-10.30
Gross margin3.78%
Operating margin-71.95%
Profit margin-41.86%
Return on equity-26.91%
Return on assets-14.74%
Debt / equity41.94
Current ratio2.13
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $460.16M | $398.99M | $266.72M | $215.04M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$175.54M | -$257.10M | -$334.62M | -$443.29M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$175.54M | -$257.10M | -$334.62M | -$443.29M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.46 | +27.9% |
| Mar 2026 | -0.53 | -0.46 | +12.6% |
| Dec 2025 | -0.42 | -0.46 | -8.5% |
| Sep 2025 | -0.29 | -0.33 | -12.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.58 | 5 | $108.82M | -6.3% |
| Next quarter | -0.64 | 5 | $113.95M | -10.7% |
| Current year | -2.29 | 9 | $422.64M | -8.1% |
| Next year | -2.06 | 10 | $568.88M | +34.6% |
Analyst targets & ownership
Mean target$32.39
High target$50.00
Low target$24.25
Implied upside25.06%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy2 / 9
Hold1
Sell / Strong sell0 / 0
Held by insiders2.15%
Held by institutions38.39%
Institutions holding128
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+916.17K
Net buying
Buy transactions
30
1.45M shares
Sell transactions
28
531.94K shares
Net transactions
+58
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
2.42M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | CHEN YAJING Chief Financial Officer |
— | 1.25K | — | Direct |
| Aug 12, 26 | LIS WILLIAM DAVID Director |
SELL | 8.51K | $212.65K | Direct |
| Aug 11, 26 | CHEN YAJING Chief Financial Officer |
SELL | 619 | $15.47K | Direct |
| Jul 2, 26 | DU YING SAMANTHA Chief Executive Officer |
— | 29.05K | — | Direct |
| Jul 1, 26 | GAYNOR RICHARD BRIAN M.D. Director |
BUY | 1.74K | $33.07K | Direct |
| Jun 30, 26 | DU YING SAMANTHA Chief Executive Officer |
SELL | 7.03K | $130.22K | Direct |
| Jun 29, 26 | DU YING SAMANTHA Chief Executive Officer |
— | 17.97K | — | Direct |
| Jun 26, 26 | CHEN YAJING Chief Financial Officer |
SELL | 2.26K | $39.53K | Direct |
| Jun 26, 26 | DU YING SAMANTHA Chief Executive Officer |
SELL | 24.54K | $428.55K | Direct |
| Jun 26, 26 | EDMONDSON FRAZOR TITUS III Officer |
SELL | 4.10K | $71.64K | Direct |
| Jun 25, 26 | DU YING SAMANTHA Chief Executive Officer |
— | 58.80K | — | Direct |
| Jun 25, 26 | EDMONDSON FRAZOR TITUS III Officer |
— | 14.60K | — | Direct |
| Jun 25, 26 | CHEN YAJING Chief Financial Officer |
— | 6.25K | — | Direct |
| Jun 22, 26 | LIS WILLIAM DAVID Director |
SELL | 7.04K | $127.35K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AMADO RAFAEL |
President | 57.02K | Sale |
DIEKMAN JOHN DAVID |
Director | 122.14K | Stock Award(Grant) |
DU YING SAMANTHA |
Chief Executive Officer | 1.22M | Conversion of Exercise of derivative security |
GAYNOR RICHARD BRIAN M.D. |
Director | 80.74K | Purchase |
LEUNG NISA BERNICE WING-YU |
Director | 96.30K | Stock Award(Grant) |
MOULDER LEON OLIVER JR. |
Director | 94.97K | Stock Award(Grant) |
SMILEY JOSHUA L |
President | 117.60K | Sale |
VOUNATSOS MICHEL PERICLES |
Director | 72.79K | Stock Award(Grant) |
WIRTH PETER KARL J.D. |
Director | 416.12K | Stock Award(Grant) |
YING DU |
Chief Executive Officer | 526.03K | Sale |
Moving averages & technicals
SMA 10
25.69
+0.80% from price
SMA 20
22.41
+16.05% from price
SMA 50
20.43
+27.33% from price
SMA 100
20.30
+27.61% from price
SMA 200
19.65
+32.34% from price
EMA 12
24.72
+4.75% from price
EMA 26
22.85
+13.37% from price
EMA 50
21.42
+20.89% from price
RSI (14)
71.6
Overbought
MACD (12,26,9)
1.88
Hist 0.34
ATR (14)
1.43
5.51% of price
Realised vol 30D
65.2%
Annualised
Bollinger upper
29.44
20, 2σ
Bollinger lower
15.38
20, 2σ
50 / 200 cross
Golden
20.43 vs 19.65
Trend bias
Above 200
+32.34%
Risk profile
Beta vs SPY
1.00
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
65.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-53.5%
Peak to trough
Max drawdown 5Y
-90.9%
Peak to trough
ATR 14
1.43
5.51% of price
Beta (reported)
0.78
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.83
Call-heavy session
Put / call open interest
0.72
Positioning, not flow
Max pain
17.50
-32.7% from spot
ATM implied vol
58.5%
Nearest strike to spot
Skew (10% OTM)
+0.1%
Puts bid over calls
Call volume
53
Contracts, this expiry
Put volume
44
Contracts, this expiry
Heaviest call OI
25.00
249 contracts
Heaviest put OI
17.50
164 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?
Insider Monkey · 2d ago
Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics
GlobeNewswire · 2d ago
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
MT Newswires · 3d ago
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
GlobeNewswire · 4d ago
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Business Wire · 5d ago
Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
MT Newswires · 9d ago
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
MT Newswires · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.